Indeed, a SIRT1 inhibitor (tenovin-6) increased the expression of the p53 target gene in chronic myeloid leukemia CD34+ cells by activating p53 transcriptional activity123. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.